Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from SanBio Co ( (JP:4592) ) is now available.
SanBio Co., Ltd. announced the recording of non-operating expenses and deferred income taxes for the first half of the fiscal year ending January 31, 2026. The company reported a foreign exchange loss of 518 million yen due to currency fluctuations, along with financing expenses and bond interest totaling 47 million yen. Additionally, deferred income taxes amounted to negative 485 million yen. These financial adjustments are expected to impact the company’s earnings performance, reflecting the challenges posed by currency volatility and financial commitments.
The most recent analyst rating on (JP:4592) stock is a Hold with a Yen2100.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd. operates in the biotechnology industry, focusing on the development of regenerative cell therapies. The company is primarily engaged in creating innovative treatments for neurological disorders and other medical conditions, aiming to address unmet medical needs.
Average Trading Volume: 2,887,422
Technical Sentiment Signal: Buy
Current Market Cap: Yen170.1B
See more insights into 4592 stock on TipRanks’ Stock Analysis page.